Overview

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy.
Phase:
Phase 3
Details
Lead Sponsor:
NeurogesX
Treatments:
Capsaicin